key: cord-0036210-z56v56od
authors: Kneyber, Martin C. J.
title: Hematologic Emergencies in the PICU
date: 2014-05-28
journal: Pediatric Critical Care Medicine
DOI: 10.1007/978-1-4471-6416-6_20
sha: fddc904ac0bfe4b4bbcd0310b4fa3c9e2beb8a44
doc_id: 36210
cord_uid: z56v56od

The pediatric critical care physician is frequently challenged by hematologic abnormalities in critically ill children admitted to the pediatric intensive care unit (PICU). The challenge is to differentiate between primary hematologic emergencies that require critical care interventions and abnormalities secondary to other disease conditions. It is therefore necessary for the pediatric critical care physician to collaborate with the pediatric hematologist when managing such patients. This chapter summarizes some of the most common hematologic emergencies of red blood cell (RBC), white blood cell (WBC), or platelet disorders observed in critically ill children that may require attention of the pediatric critical care physician.

The pediatric critical care physician is frequently challenged by hematologic abnormalities in critically ill children admitted to the pediatric intensive care unit (PICU). The challenge is to differentiate between primary hematologic emergencies that require specifi c interventions and abnormalities secondary to other disease conditions. The purpose of this chapter is to summarize some of the most common hematologic emergencies seen in critically ill children that are associated with red blood cell (RBC), white blood cell (WBC) or platelet disorders. Transfusion medicine, oncologic emergencies, and coagulation disorders are discussed in other chapters. Of importance, many patients admitted for other reasons may have underlying disorders of elements of blood. It is beyond the scope of this chapter to go into detail about many of these disorders. The reader is kindly referred to books on pediatric hematology. As a consequence, it is therefore necessary for the pediatric critical care physician to collaborate with the pediatric hematologist when managing such patients.

classifi ed as resulting from underproduction, impaired maturation, or increased turn-over or destruction (i.e. hemolysis) of RBCs. Hemolysis can be attributed to numerous causes originating from either intracellular or extracellular disorders, including RBC membrane defects, abnormal erythrocyte metabolism, immune mediated hemolysis (for instance ABO mismatch or auto-immune mediated hemolysis), and primary hemoglobinopathies such as thalassemias and sickle cell disease (SCD). Diseases leading to anemia can be identifi ed by symptoms and diagnostic investigations (Table 20. 2 ), of which the cell indices provide important information, in particular the mean corpuscular volume (MCV) ( Table 20. 3 ) [ 3 ] .

Irrespective of its cause, anemia results in decreased O 2 carrying capacity and ultimately decreased O 2 delivery (DO 2 ). Clinical symptoms vary widely and include pallor, nausea, vomiting, weakness, fatigue, irritability, tachycardia, tachypnea and edema. However, it is not clear what the impact of anemia itself is on outcome of critically ill children. A Hb < 5 g/dL has been associated with increased mortality in non-critically ill children [ 4 -6 ] . Furthermore, anemia was identifi ed as an independent predictor for mortality in critically ill adults, whereas one group of investigators did not observe such an association in a heterogeneous group of critically ill children [ 7 , 8 ] . Importantly, the landmark paper from the TRIPICU study has clearly shown that stable critically ill children can tolerate a Hb of 7 g/dL without serious complications [ 9 ] . In this multicenter prospective study comprising 637 stable critically ill children the occurrence of new or progressive multiple organ dysfunction syndrome was similar between patients randomized to a restrictive transfusion strategy (threshold Hb 7 g/dL) and liberal transfusion strategy (threshold Hb 9.5 g/dL) within 7 days of PICU admission. A post-hoc analysis of postsurgical PICU patients and children after cardiac surgery showed similar fi ndings [ 10 , 11 ] . At present, no data is available identifying a proper threshold for unstable critically ill children such as those with severe hypoxemia or hemodynamic compromise. Therefore, the decision to treat anemia is determined by the underlying cause, the acuteness, and the physiologic status of the child.

There are a number of diseases that lead to underproduction of erythrocytes and anemia, whereas iron defi ciency or lead poisoning are well known causes of impaired maturation of RBCs. The majority of these conditions are chronic, with the exception of bone marrow failure affecting a single or even multiple cell lineages causing pancytopenia. The most common cause of acquired pancytopenia in the PICU is leukemia -either at presentation or as a consequence of chemotherapy or irradiation. Alternatively, many drugs often used in the PICU (e.g., antibiotics, ibuprofen, captopril and phenytoin) and infectious agents such as Parvovirus B19, hepatitis virus, Ebstein-Barr virus, cytomegalovirus, tuberculosis and human immunodefi ciency virus are important causes of bone marrow failure. Of importance, pancytopenia 

Many hematological diseases may result in severe hemolytic anemia, such as sickle cell disease (SCD), thalassemias and (non-) immune mediated hemolysis.

Sickle cell disease (SCD) is one of the most important causes of hemolytic anemia that may bring a patient into the PICU. SCD is the general term for all phenotypes related to mutations in the hemoglobin gene found at chromosome 11p15.4 that are characterized by red cell sickling following hemoglobin deoxygenation, chronic hemolysis, recurrent vaso-occlusion, and ischemic injury to various organs [ 12 ] . Sickle cell anemia (SCA) is the most common form of SCD. It is an autosomal recessive disease caused by the substitution of valine for glutamine at the sixth amino acid position of the beta chain of the hemoglobin gene. Sickle cell trait (SCT) differs from SCA in that it is a heterozygous condition and does not cause active disease. SCA primarily affects individuals from African, Mediterranean, Indian, and Middle Eastern descent, although there is also a high incidence among Hispanic individuals from the Caribbean, Central American and some South American countries [ 13 ] . Factors that promote sickling include desaturation of hemoglobin (either by failure to oxygenate in the lungs, diminished DO 2 or increased tissue extraction of oxygen), and increased microvascular transit time as seen in dehydration or vasoconstriction (Table 20 .4 ). The number of RBCs that sickle depends on the extent and duration of deoxygenation, the proportion of abnormal ß-chain in the Hb (HbS) of affected cells, and the presence of fetal Hb in the erythrocytes. The conformational change in HbS enables polymerization between Hb molecules. Children with SCD may carry up to 90-100 % of HbS. HbF effectively reduces the concentration of HbS [ 14 ] . Hydroxyurea promotes the formation of HbF, hence its use is recommended in all patients with SCD to prevent SCD related complications [ 15 ] . Next to this, increased endothelial activity with production of endothelin and circulation of soluble cell adhesion molecules promotes sickle cell adhesion [ 16 , 17 ] . Activation of platelets, adhesion of neutrophils, and proinfl ammatory cytokine release further promote sickling.

Many life-threatening complications of SCD result from occlusion of the microcirculation. The fi rst includes acute splenic sequestration crisis and transient aplastic crisis (TAC). TAC occurs in patients with SCD when there is a transient suppression of erythropoiesis following infection with a viral agent such as human parvovirus B19. This usually lasts for several days. Clinical symptoms rarely include hemodynamic instability; hence, clinical management is mainly supportive. Acute chest syndrome (ACS), cerebrovascular accidents (CVA) and vaso-occlusive crises (VOC) are other manifestations of occlusion of the microcirculation.

Acute splenic sequestration crisis is characterized by a sudden pooling of blood in the splenic sinusoids resulting in severe anemia. It typically occurs in children between 10 and 27 months of age, though it can also occur in young infants. It is relatively uncommon in older children because they develop functional asplenia over time, caused by repeated infarctions and subsequent fi brosis of the spleen, or autosplenectomy. Acute splenic sequestration crisis often occurs during bacterial or viral infection. Symptoms can range from mild to severe and include splenomegaly and symptoms of intravascular volume depletion. Laboratory investigations show an acute drop in Hb (>2 g/dL), reticulocytosis, thrombocytopenia, and leucopenia. The mainstay of treatment is to restore circulating blood volume and hemodynamic stability through infusion of volume expanders, and by repeated blood or exchange transfusions. One group of investigators has reported substantial mortality (35 %) when the Hb level dropped > 4 g/dL. Performing a splenectomy after a fi rst crisis is controversial because of the infectious risks associated with splenectomy. Alternatively, close long-term monitoring of the child may avoid the need for splenectomy.

ACS is one of the most common complications of SCD and is associated with signifi cant morbidity and mortality (mortality rates ranging from 1.8 to 5 %) [ 18 ] . Pulmonary microvascular sequestration of sickled RBCs initiates ACS, leading to acute lung injury (ALI) or even ARDS necessitating mechanical ventilation [ 19 ] . Clinical symptoms include fever, (productive) cough, chest pain, dyspnea, hemoptysis, and hypoxia. Of note, these symptoms may not be present initially but frequently develop during disease course in response to other precipitating events. Laboratory investigations show leukocytosis and presence of mainly isolated upper or middle lobe consolidations on chest radiograph. Pleural effusions are less common, in contrast with adults. Repetitive episodes of ACS may have signifi cant long-term consequences such as pulmonary fi brosis, pulmonary hypertension, or cor pulmonale. Pulmonary hypertension in ACS is associated with increased mortality in adults, but this does not seem to be the case for children and adolescents [ 20 ] .

The exact pathophysiological mechanisms of ACS remains to be elucidated, but precipitating factors include bacterial and viral infections (especially in young children in winter months), higher steady-state Hb level, increased neutrophil count, and atelectasis (Table 20.5 ) [ 22 ] . Patients at risk for ACS may be identifi ed by serum secretory phospholipase A2 levels [ 23 ] , though this test is not widely available.

Many patients with SCD also suffer from hyperreactive airways or asthma [ 24 ] .

Treatment of ACS centers on treating the underlying pulmonary infection (if presumed present) and preventing infarction of lung tissue. Treating the infection prevents hypoxia and acidosis, two important risk factors of sickling; prevention of infarction minimizes pain and hypoventilation (which in itself is a risk for pulmonary infection). Therefore, conventional treatment includes oxygen, intravenous fl uid hydration, broad-spectrum antibiotics, pain medications and transfusion therapy. Transfusion alone often results in signifi cant clinical improvement [ 22 ] . Exchange transfusion aimed at decreasing HbS <30 % is indicated when the patient is severely hypoxemic or has widespread pulmonary infarction. Bronchoconstriction needs to be treated, if present. Adjunctive therapeutic interventions have emerged including corticosteroids and nitric oxide (NO). Dexamethasone limited the severity in one small study of 43 patients, but was also associated with increased rehospitalization after 72 h [ 25 ] . The use of NO in critically ill children with ACS has so far only been described in case reports; hence its routine use cannot be recommended.

CVAs are the other predominant leading cause of morbidity and mortality in children with homozygous SCD admitted to the PICU [ 26 ] . By the age of 20 years, approximately 11 % of all patients will have suffered from infarcts, most frequently resulting from stenosis of large cerebral arteries (mainly the distal internal carotid artery and the proximal middle cerebral artery) [ 27 ] . Strikingly, approximately 15-25 % of patients with SCD have silent cerebral infarction [ 28 ] . Recent or recurrent ACS is a signifi cant risk factor for the later development of stroke, which suggests that repeated damage to the endothelium may contribute. Abnormal cerebral fl ow on transcranial Doppler (TCD) ultrasound seems to be another risk factor in children [ 29 ] . Older children and adolescent suffer more often from hemorrhagic stroke caused Based on data from Ref. [ 21 ] by ruptured aneurysms. Importantly, chronic transfusion therapy in children with SCA signifi cantly decreased the occurrence of CVAs [ 30 , 31 ] . The diagnosis of CVAs in patients with SCA is not different from other patients with CVA. Emergency management includes adequate oxygenation and exchange transfusion (targeted towards HbS <20 %) [ 32 ] .

VOC is a challenging and perhaps the most common complication of SCD. It is characterized by a vicious circle of sickling, micro-vascular occlusion and hypoxemia. It can occur in almost any organ in the body causing organ-specifi c symptoms, fever, leukocytosis and pain. The pain can be very severe. Bones are predominantly affected. Abdominal crises are diffi cult to discriminate from other acute or surgical abdominal diseases. Emergency management of VOC consists of adequate hydration, oxygenation, and pain control with analgesic and anti-infl ammatory drugs (i.e. opioids and non-steroidal anti-infl ammatory drugs). RBC transfusion may be indicated to break the vicious circle of sickling.

Functional asplenia is common in SCD. Patient with SCD are therefore susceptible to sepsis caused by encapsulated bacteria such as Streptococcus pneumoniae and Haemophilus infl uenzae . Sepsis is a major cause of death in children with SCD. Preventive measures such as immunization against encapsulated bacteria and prophylactic antibiotic usage have signifi cantly improved patient outcome [ 33 ] . Nonetheless, empiric broad-spectrum antibiotic therapy is indicated in children with SCD children when an infection is suspected.

The primary goal of transfusion therapy is to restore the appropriate Hb and hemotocrit (Ht) level. However, children with SCD are chronically anemic; hence, compensatory mechanisms have set in to ensure maintenance of adequate DO 2 . In addition, higher Ht levels increase blood viscosity, enhancing the risk of sickling in the microcirculation. Thus, in general RBC transfusion should be used as little as possible in children with SCD except for specifi c indications (Table 20 .6 ). However, exchange transfusions may be more indicated in critically ill children in order to minimize the risk of microvascular sickling; the primary goal would be to achieve an HbS <30 %. Children undergoing surgery under general anesthesia are at increased risk for severe complications such as acute chest syndrome, painful crises, neurologic complications (stroke, seizures) or renal failure.

Schistocytes are fragments of RBCs formed by exposure to turbulence, shear stress, pressure fl uctuation and collision with surfaces (schistocytosis). This form of hemolysis is caused by micro-angiopathic hemolysis (i.e. at the level of the arterioles), macro-angiopathic hemolysis (for instance in hemangiomas), and mechanical hemolysis in patients on extra-corporeal life support (ECLS). The most frequent causes of micro-angiopathic hemolysis in children presenting to the PICU include disseminated intravascular coagulation (DIC), hemolytic-uremic syndrome (HUS) and subacute bacterial endocarditis. A triad consisting of hemolysis, thrombocytopenia, and acute renal failure (ARF) defi nes HUS. It is part of a spectrum that includes thrombocytopenic thrombotic purpura, which is seen more often in adults and is characterized by a more important neurologic involvement. Numerous -mainly infectious -agents trigger HUS; Escherichia coli O157:H7 is the most common, and it is frequently related to insufficient heating of meat. The pathophysiology of HUS is not clear, but likely involves injury to the endothelial cells involving ADAMTS-13 (a von Willebrand factor cleavage protein) and factor H (a complement C3 convertase inhibitor) [ 34 ] . This causes microthrombi and fi brin strands in arterioles that damage RBCs and cause platelet aggregation leading to anemia and thrombocytopenia. Children with HUS frequently present with acute renal failure. Other features include bowel involvement mimicking acute abdomen and central nervous involvement including seizures or altered consciousness. Therapy is mainly supportive and may require renal replacement therapy. Plasma exchange therapy may be benefi cial [ 35 ] and is reviewed elsewhere in this textbook. Platelet transfusion is rarely indicated.

Macro-angiopathic hemolysis may be observed in patients in whom prosthetic heart valves have been implanted. Critical care intervention is only required in children with macro-angiopathic hemolysis when complications of the Kasabach-Merritt syndrome develop. Mechanical schistocytic hemolysis in patients on ECLS occurs when the blood fl ow is set above limits, small cannulas are used, large negative pressures are generated, and blood is exposed to foreign surfaces. Monitoring free Hb is used for evaluating the extent of hemolysis in children on ECLS. It is also postulated that free Hb has clinical consequences such as renal impairment, but this has yet to be elucidated [ 36 ] .

Congenital and acquired intrinsic red cell membrane defects rarely require admission to the PICU, but may be observed in patients admitted to the PICU for other reasons. Acquired membrane red cell defects are caused by burns (either direct or indirect via oxygen radicals), toxins from streptococcal or staphylococcal infection, infection, drugs (such as antibiotics) or transfusion with plasma products [ 37 -39 ] . Children with paroxysmal nocturnal hemoglobinuria (PNH) may present with venous thrombo-embolism in unusual locations and a history of recurrent sinopulmonary infection or septicemia. Thrombotic events, which can be lethal, are refractory to thrombolytic therapy [ 40 ] . Hereditary spherocytosis is a congenital red cell membrane defect that can be associated with life-threatening crises after parvovirus B19 infection, when there is an imbalance between inadequate production due to acquired bone marrow failure and hemolysis.

It is rare that patients with red cell metabolism defects need critical care, apart from patients with glucose-6-phospate defi ciency (G6PD). G6PD is an X-linked inherited disease with high prevalence rates in tropical Africa, Middle East, tropical and subtropical Asia, and some areas of the Mediterranean Sea [ 41 ] . Patients become symptomatic when the enzyme activity is less than 60 %. Glucose-6-phosphate dehydrogenase handles oxidative stress in the erythrocyte. It catalyzes the reduction of nicotinamide adenine dinucleotide phosphate (NADP) to NADPH in the hexose-monophosphate shunt, which in turn converts glutathione disulfi de to reduced gluthathione. Gluthathione is a scavenger for oxygen radicals. Patients with G6PD defi ciency may present with severe acute hemolytic anemia caused by stressors such as drugs (Table 20 .7 ), infection or notably ingestion of fava beans. Treatment consists mainly of eliminating (if possible) the precipitating agent; RBC transfusions may be indicated.

Immune-mediated hemolysis is discriminated into alloimmune and autoimmune. Alloimune hemolysis occurs when the child passively acquires RBC antibodies during transfusion with RBC preparations containing donor antibodies. Autoimmune hemolytic anemia (AHIA) occurs when a child intrinsically develops antibodies against RBCs with (primary AIHA) or without (secondary AIHA) accompanying systemic illness. Primary AIHA usually occurs after a viral infection. The child suffers from symptoms of anemia and dark urine. Because of the rapid onset, other symptoms such as jaundice or reticulocytosis may not be present. Laboratory studies show isolated anemia, low haptoglobin, spherocytes on peripheral blood smear and a positive direct antiglobulin (i.e. Coombs) test. The indirect Coombs test detects antibodies in the patients' serum. Supportive therapy includes plasma exchange. Transfusion should be avoided unless severe anemia with cardiovascular compromise occurs. Further therapy (e.g., high-dose corticosteroids) is dependent upon the type of primary AIHA, which is defi ned by the presence of IgG antibodies (suggesting warm-reactive AIHA) or complement (suggesting cold-reactive AIHA). Cold-reactive AIHA is then classifi ed by which type of antibody (IgM auto-antibody or IgG) is detected. Secondary AIHA occurs in a wide variety of disease (Table 20 .8 ). 

Thalassemias are a group of inherited disorders of hemoglobin synthesis. Although they are more common than SCD, patients with thalassemias are not often primarily seen in the PICU. Patients with the transfusion-dependent form of thalassemia (thalassemia major) may experience complications from iron overload sepsis. The risk of sepsis is increased because many patients underwent splenectomy or have indwelling vascular devices implanted for repetitive transfusion or chelation therapy [ 42 ] . Improved chelation therapy regimens have decreased the complication rate of myocardial iron overload necessitating inotropic support that was often required in adolescents with thalassemia major [ 42 ] . 

Hemophagocytic lymphohistiocytosis (HLH) syndrome is a devastating multisystem disease with a poor prognosis [ 43 ] . The initiating event of reactive HLH is unknown, but it has been associated with infectious agents such as EBV or autoimmune disorders. Congenital HLH is a malignancy. Twenty percent of HLH is familial and associated with abnormalities of a natural killer cell-derived cytotoxin (perforin). HLH is characterized by aggressive destruction of RBCs and other blood elements by macrophages in bone marrow, liver and spleen. Clinical symptoms vary and are similar to the systemic infl ammatory response syndrome (SIRS). The disease can be recognized if the patient meets at least fi ve of the following criteria: (a) fever, (b) splenomegaly, (c) cytopenias of two or more lineages, (d) hypertriglyceridemia (>3.0 mmol/L) and/or hyperfi brinogenemia (≤1.5 g/L), (e) hemophagocytosis seen in bone marrow (no malignancy seen), spleen or lymph node, (f) low or absent natural killer cell activity, (g) ferritin ≥ 500 mcg/L), and (h) soluble CD25 ≥ 2,400 U/mL) [ 44 ] . Other supportive fi ndings include CSF pleiocytosis, elevated serum transaminases, elevated bilirubin, and elevated LDH. Treatment in the PICU is supportive. The only curative option for congenital HLH is bone marrow transplantation.

An increase in circulating RBCs is termed erythrocytosis. It very rarely primarily leads to critical care intervention, but may be seen in patients admitted for any other reason. Secondary erythrocytosis originates from hypoxia such as in patients with right-to-left shunting cardiac lesion or pulmonary disease and patients living in high altitude, whereas spurious erythrocytosis is caused by dehydration, hemoconcentration or polyuria. Patients with primary erythrocytosis have normal levels of erythropoietin, but it is increased in those with secondary erythrocytosis. Arterial hematocrit >65 % may aggravate tissue hypoxia, cause thrombosis and necessitate the use of reduction exchange transfusions. The volume of blood that needs to be exchanged is calculated by multiplying the child's estimated blood volume by the desired reduction in hematocrit. In the infant, the removal rate should not exceed 2 mL/kg/min.

The type of leukocytosis is defi ned by specifying the WBC type along with the underlying cause of the increase. Stress mobilizes neutrophils from the bone marrow into the circulation or shifts marginated neutrophils. These are circulating neutrophils that were not active but can be mobilized in times of stress. True neutrophilia results from infection (both bacterial and viral), the band form is considered to be very suggestive for bacterial infection and thus routinely used in daily critical care [ 45 ] . In severe infections, neutropenia may occur because of insuffi cient formation of new neutrophils. Leukemoid reactions (i.e. neutrophils > 50,000 cells/microL) can be triggered by various diseases but can only be discriminated from true leukemia through laboratory studies including marrow histology. Of particular concern are children with trisomy 21 who initially may have leukemoid reactions that develop into myeloid leukemias. Lymphocytosis is classically known to occur in Bordetella pertussis infection and following viral infection, whereas lymphopenia is often transient resulting from viral, fungal or parasitic infections. Yet, one should be aware of chronic underlying diseases including HIV infection. Eosinophilia is associated with allergic conditions or parasitic infections. Monocytosis is commonly caused by infections (tuberculosis, subacute bacterial endocarditis, syphilis, brucellosis, infectious mononucleosis, malaria) or autoimmune disorders (such as systemic lupus erythematosus and sarcoidosis).

Thrombocytopenia Thrombocytopenia in critically ill children is relatively common and results from underproduction, overconsumption, or both (as for instance during sepsis). In addition, it is not uncommon to observe thrombocytopenia caused by inadequate sampling or technical impairments in the laboratory. In general, the underlying cause is usually determined easily. If not, then additional investigations including thrombopoietin levels need to be measured [ 46 ] . The clinical spectrum of thrombocytopenia ranges from bruising, petechia and epistaxis to signifi cant, life threatening bleeding. Hence, the decision when to transfuse platelets depends on the risk of bleeding and underlying disease.

There are many causes of thrombocytopenia caused by increased consumption of platelets, of which DIC and HUS are the most predominant. Hemorrhage and cardiopulmonary bypass-related thrombocytopenia are also common. Burns causes sequestration of platelets in proportion to the area injured -persistence of thrombocytopenia in these patients may indicate DIC or sepsis. Meningococcemia is notorious for causing purpura fulminans, but this may occur also when infected with other agents. In patients with meningococcemia, the initial and serial assessment of platelet and neutrophil count may be used as a prognostic score [ 47 , 48 ] . Likewise, platelet count is also predictive for the need of renal support in patients with Rocky Mountain spotted fever. Foreign surfaces in ECLS systems used in cardiac surgery activate and absorb platelets. This can be prevented by optimizing anticoagulant therapy and heparin coating of circuit components, timely changes of the circuit and post membrane platelet transfusion.

Additional measures suggested include the use of aprotonin in young children [ 49 ] .

Idiopathic thrombocytopenic purpura (ITP) is caused by splenic phagocytosis of antibody-coated platelets [ 50 ] . The acute form is self-limiting; it cures spontaneously within several weeks following the precipitating viral infection. Approximately 20 % of affected children develop chronic ITP (i.e. < 150,000 cells/mcL). The mortality in ITP is very low (i.e. 1 %) and mainly caused by intracranial hemorrhage. Diagnosis and treatment is in adherence with guidelines from the American Society of Hematology [ 51 ] . Heparininduced thrombocytopenia is relatively uncommon in critically ill children. It is caused by the formation of autoantibodies against heparin-platelet protein four complexes. In addition, the IgG antibodies activate platelets resulting in a prothrombotic state.

Reduced platelet synthesis rarely constitutes an acute problem.

Thrombocytosis is defi ned as a platelet count >450,000 cells/ mcL. Primary thrombocytosis is very uncommon in children, but secondary thrombocytosis has various causes including Kawasaki disease. The major complication of thrombocytosis is thrombosis, but it is unknown at what threshold to start preventive measures. In patients with Kawasaki, aspirin is initiated to prevent coronary thrombus formation.

Anemia, blood loss, and blood transfusions in North American children in the intensive care unit

Red blood cell transfusion in paediatric critical care

Hematologic emergencies in the pediatric emergency room

Blood transfusion for severe anaemia in children in a Kenyan hospital

Effect of blood transfusion on survival among children in a Kenyan hospital

Longitudinal evaluation of severely anemic children in Kenya: the effect of transfusion on mortality and hematologic recovery

The CRIT study: anemia and blood transfusion in the critically ill-current clinical practice in the United States

Red blood cell transfusion in critically ill children is independently associated with increased mortality

Transfusion strategies for patients in pediatric intensive care units

Red blood cell transfusion threshold in postsurgical pediatric intensive care patients: a randomized clinical trial

Comparison of two red-cell transfusion strategies after pediatric cardiac surgery: a subgroup analysis

Coagulase-negative staphylococcal infections

Global epidemiology of haemoglobin disorders and derived service indicators

Pathogenesis and treatment of sickle cell disease

Hydroxyurea for sickle cell anemia: what have we learned and what questions still remain?

Plasma endothelin-1, cytokine, and prostaglandin E2 levels in sickle cell disease and acute vaso-occlusive sickle crisis

Effect of red cell exchange transfusion on plasma levels of infl ammatory mediators in sickle cell patients with acute chest syndrome

Mortality in sickle cell disease. Life expectancy and risk factors for early death

Causes and outcomes of the acute chest syndrome in sickle cell disease. National acute chest syndrome study group

Pulmonary hypertension in children with sickle cell disease

Roger's textbook of pediatric intensive care

How I, treat acute chest syndrome in children with sickle cell disease

Transfusion prevents acute chest syndrome predicted by elevated secretory phospholipase A2

Asthma management: reinventing the wheel in sickle cell disease

Benefi cial effect of intravenous dexamethasone in children with mild to moderately severe acute chest syndrome complicating sickle cell disease

Outcome of children with sickle cell disease admitted to intensive care -a single institution experience

Cerebrovascular accidents in sickle cell disease: rates and risk factors

Silent infarction as a risk factor for overt stroke in children with sickle cell anemia: a report from the cooperative study of sickle cell disease

Long-term stroke risk in children with sickle cell disease screened with transcranial Doppler

Prevention of a fi rst stroke by transfusions in children with sickle cell anemia and abnormal results on transcranial Doppler ultrasonography

Discontinuing prophylactic transfusions used to prevent stroke in sickle cell disease

Current concepts in the management of stroke in children with sickle cell disease

Pneumococcal vaccines for sickle cell disease

Genetics and complement in atypical HUS

Therapeutic apheresis in the treatment of hemolytic uremic syndrome in view of pathophysiological aspects

Pathogenetic mechanisms in experimental hemoglobinuric acute renal failure

Caffeic acid phenethyl ester improves oxidative erythrocyte damage in a rat model of thermal injury

Mode of action of beta-barrel pore-forming toxins of the staphylococcal alpha-hemolysin family

Streptococcal beta-hemolysins: genetics and role in disease pathogenesis

Paroxysmal nocturnal haemoglobinuria: long-term follow-up and prognostic factors. French society of haematology

Glucose-6-phosphate dehydrogenase defi ciency

Complications of beta-thalassemia major in North America

Familial and acquired hemophagocytic lymphohistiocytosis

Hemophagocytic lymphohistiocytosis: updates and evolving concepts

Fever in the new millennium: a review of recent studies of markers of serious bacterial infection in febrile children

Human thrombopoietin levels are high when thrombocytopenia is due to megakaryocyte defi ciency and low when due to increased platelet destruction

Early severe neutropenia and thrombocytopenia identifi es the highest risk cases of severe meningococcal disease

A normal platelet count at admission in acute meningococcal disease does not exclude a fulminant course

The use of aprotinin in pediatric patients: a review

Childhood immune thrombocytopenic purpura: diagnosis and management

The child with immune thrombocytopenic purpura: is pharmacotherapy or watchful waiting the best initial management? A panel discussion from the 2002 meeting of the American society of pediatric hematology/oncology